Cerus Corporation (CERS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cerus Corporation (CERS) has a cash flow conversion efficiency ratio of 0.095x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($6.20 Million) by net assets ($64.97 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cerus Corporation - Cash Flow Conversion Efficiency Trend (1997–2025)
This chart illustrates how Cerus Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Cerus Corporation for a breakdown of total debt and financial obligations.
Cerus Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cerus Corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhejiang Shapuaisi Pharmaceutical Co Ltd
SHG:603168
|
0.005x |
|
Hiper Global Ltd
TA:HIPR
|
0.127x |
|
Shandong Zhangqiu Blower Co Ltd
SHE:002598
|
-0.016x |
|
Firan Technology Group Corporation
TO:FTG
|
0.071x |
|
Jiangsu Hongde Special Parts Co.Ltd.
SHE:301163
|
0.012x |
|
Alvarium Tiedemann Holdings Inc.
NASDAQ:ALTI
|
-0.004x |
|
Shanghai Kaichuang Marine International Co Ltd
SHG:600097
|
0.039x |
|
Flagship Communities Real Estate Investment Trust
TO:MHC-U
|
0.026x |
Annual Cash Flow Conversion Efficiency for Cerus Corporation (1997–2025)
The table below shows the annual cash flow conversion efficiency of Cerus Corporation from 1997 to 2025. For the full company profile with market capitalisation and key ratios, see Cerus Corporation market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $64.97 Million | $11.36 Million | 0.175x | -12.42% |
| 2024-12-31 | $56.90 Million | $11.36 Million | 0.200x | +124.72% |
| 2023-12-31 | $53.44 Million | $-43.17 Million | -0.808x | -116.20% |
| 2022-12-31 | $68.56 Million | $-25.61 Million | -0.374x | +5.70% |
| 2021-12-31 | $85.62 Million | $-33.92 Million | -0.396x | +1.63% |
| 2020-12-31 | $103.81 Million | $-41.81 Million | -0.403x | +64.92% |
| 2019-12-31 | $57.05 Million | $-65.50 Million | -1.148x | -210.54% |
| 2018-12-31 | $84.52 Million | $-31.25 Million | -0.370x | +72.44% |
| 2017-12-31 | $38.94 Million | $-52.23 Million | -1.341x | -44.81% |
| 2016-12-31 | $57.79 Million | $-53.53 Million | -0.926x | -71.69% |
| 2015-12-31 | $94.77 Million | $-51.13 Million | -0.540x | +43.47% |
| 2014-12-31 | $41.71 Million | $-39.81 Million | -0.954x | -52.43% |
| 2013-12-31 | $42.80 Million | $-26.80 Million | -0.626x | +14.03% |
| 2012-12-31 | $19.11 Million | $-13.92 Million | -0.728x | +14.67% |
| 2011-12-31 | $18.31 Million | $-15.63 Million | -0.854x | -43.56% |
| 2010-12-31 | $23.73 Million | $-14.11 Million | -0.595x | +13.03% |
| 2009-12-31 | $21.45 Million | $-14.66 Million | -0.684x | +32.16% |
| 2008-12-31 | $34.28 Million | $-34.55 Million | -1.008x | -61.36% |
| 2007-12-31 | $59.89 Million | $-37.40 Million | -0.625x | -329.42% |
| 2006-12-31 | $100.97 Million | $-14.69 Million | -0.145x | +65.68% |
| 2005-12-31 | $35.27 Million | $-14.95 Million | -0.424x | +28.46% |
| 2004-12-31 | $21.49 Million | $-12.73 Million | -0.592x | +46.92% |
| 2003-12-31 | $52.53 Million | $-58.62 Million | -1.116x | -12.62% |
| 2002-12-31 | $56.17 Million | $-55.65 Million | -0.991x | -140.40% |
| 2001-12-31 | $106.75 Million | $-44.00 Million | -0.412x | -5.41% |
| 2000-12-31 | $81.92 Million | $-32.03 Million | -0.391x | +61.25% |
| 1999-12-31 | $33.00 Million | $-33.30 Million | -1.009x | +86.48% |
| 1998-12-31 | $1.30 Million | $-9.70 Million | -7.462x | -911.35% |
| 1997-12-31 | $22.50 Million | $-16.60 Million | -0.738x | -- |
About Cerus Corporation
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company also offer… Read more